[{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"7","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Abexinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Oncternal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Ibrutinib","moa":"||Inactive tyrosine-protein kinase transmembrane receptor ROR1","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Leukocyte surface antigen CD47","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"7","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"1","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Ohio State University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Ohio State University","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Ohio State University"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"7","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Oncternal Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Celgene Corporation"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase IV","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Johnson & Johnson","highestDevelopmentStatusID":"11","companyTruncated":"Pharmacyclics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine | Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine | Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Johnson & Johnson Innovative Medicine | Celgene Corporation"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Celgene Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Celgene Corporation"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"AstraZeneca | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ AstraZeneca | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ AstraZeneca | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pharmacyclics \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"PCI-32765","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"PCI-32765","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"PCI-32765","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Deuterium Oxide","moa":"Water","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pharmacyclics","highestDevelopmentStatusID":"7","companyTruncated":"Pharmacyclics \/ Pharmacyclics"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Michael Choi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Michael Choi","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacyclics \/ Michael Choi"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Brian Jonas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"B-lymphocyte antigen CD19 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Brian Jonas","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Brian Jonas"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Brian Jonas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Brian Jonas","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacyclics \/ Brian Jonas"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Pamela Munster","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Abexinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Pamela Munster","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacyclics \/ Pamela Munster"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Andrew Rezvani","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Andrew Rezvani","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Andrew Rezvani"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Joseph Tuscano","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Joseph Tuscano","highestDevelopmentStatusID":"10","companyTruncated":"Pharmacyclics \/ Joseph Tuscano"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Kami Maddocks","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Kami Maddocks","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Kami Maddocks"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Michael Choi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Michael Choi","highestDevelopmentStatusID":"15","companyTruncated":"Pharmacyclics \/ Michael Choi"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Brian Jonas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Brian Jonas","highestDevelopmentStatusID":"6","companyTruncated":"Pharmacyclics \/ Brian Jonas"},{"orgOrder":0,"company":"Pharmacyclics","sponsor":"Jennifer Woyach","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"BK1301","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Pharmacyclics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacyclics \/ Jennifer Woyach","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacyclics \/ Jennifer Woyach"}]
Find Clinical Drug Pipeline Developments & Deals by Pharmacyclics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
